Targeted gene modification by parvoviral vectors

• US 20110097804A1
• Filed: 04/24/2003
• Published: 04/28/2011
• Est. Priority Date: 04/24/1997
• Status: Active Grant

• Current Assignee: University of Washington
• Original Assignee: University of Washington
• Inventors: Hirata, Roli K., Russell, David W.
• Granted Patent: US 7,972,856 B2
• Time in Patent Office: Days
• US Class Current: 435/463
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector

Abstract

This invention provides methods for obtaining targeted gene modification in vertebrate cells using parvoviral vectors, including adeno-associated virus (AAV). The parvoviral vectors used in the methods of the invention are capable of targeting a specific genetic modification to a preselected target locus in a cellular genome by homologous pairing.

Claims

1-73. -73. (canceled)

74. An in vitro method of producing a vertebrate cell having a genetic modification at a preselected genomic target locus, the method comprising:

(i) transducing into the vertebrate cell an effective amount of a recombinant parvovirus particle genome that comprises;

a) a targeting construct which comprises a DNA sequence which is substantially identical to the genomic target locus except for the modification being introduced, wherein the modification being introduced is flanked by regions substantially identical to the genomic target locus, said regions being at least 100 nucleotides in length; and

b) at least one parvoviral inverted terminal repeat (ITR) flanking the targeting construct; and

(ii) determining if the genomic target locus has the introduced genetic modification, wherein the targeting construct facilitates homologous pairing between the targeting construct and the genomic target locus resulting in the genetic modification being introduced into the genomic target locus.

75. The method of claim 74, wherein the recombinant parvovirus particle genome further comprises a DNA that is exogenous to the vertebrate cell, wherein the exogenous DNA is preselected for modification of the genomic target locus.

76. The method of claim 75, wherein the exogenous DNA comprises a selection marker that is functional in the vertebrate cell.

78. The method of claim 74, wherein the modification comprises one or more deletions, insertions, substitutions, or a combination thereof.

79. The method of claim 74, wherein the method further comprises introducing a modification at one or more additional preselected genomic target loci by transducing into the vertebrate cell a recombinant parvovirus particle genome comprising a targeting construct that comprises a DNA sequence which is substantially identical to each of the additional genomic target loci except for the modification being introduced.

80. The method of claim 79, wherein both targeting constructs are present in a single parvoviral particle genome.

81. The method of claim 74, wherein a DNA sequence of the genomic target locus is modified, the DNA sequence being selected from the group consisting of a transcriptional regulatory region, a splice signal, a sequence involved in DNA replication, a matrix attachment point, a chromosomal recombination hotspot, a structural gene, or a coding region for a signal sequence, and portions thereof.

82. The method of claim 81, wherein the DNA sequence comprises a structural gene and the modification results in an amino acid substitution, deletion, insertion, or a combination thereof, in a polypeptide encoded by the gene.

83. The method of claim 81, wherein the DNA sequence comprises a transcriptional regulatory region selected from the group consisting of a promoter, an enhancer, a response element, a transcription termination signal, and a locus control region.

84. The method of claim 83, wherein a gene under the control of the modified transcriptional regulatory region is expressed at a different level than that at which the gene is expressed under equivalent conditions when the gene is under the control of the unmodified transcriptional regulatory region.

85. The method of claim 84, wherein the gene under the control of the modified transcriptional regulatory region is expressed at a higher level than that at which the gene is expressed under equivalent conditions when the gene is under the control of the unmodified transcriptional regulatory region.

86. The method of claim 85, wherein the gene under the control of the modified transcriptional regulatory region is expressed under conditions that do not result in expression of the gene when under the control of the unmodified transcriptional regulatory region.

87. The method of claim 84 wherein the transcriptional regulatory region is made inducible by the modification.

88. The method of claim 84, wherein the gene under the control of the modified transcriptional regulatory region is expressed at a lower level than that at which the gene is expressed under equivalent conditions when the gene is under the control of the unmodified transcriptional regulatory region.

89. The method of claim 88, wherein a gene under the control of the transcriptional regulatory region is not expressed by a cell having the modification under conditions that result in expression of the gene when under the control of the unmodified transcriptional regulatory region.

90. The method of claim 74, wherein the vertebrate cell is a replicating cell.

91. The method of claim 74, wherein the vertebrate cell is a mammalian cell.

92. The method of claim 91, wherein the mammalian cell is a human cell.

93. The method of claim 92, wherein the human cell is a human fibroblast cell.

94. The method of claim 74, wherein the vertebrate cell is obtained from a cell line.

95. The method of claim 74, wherein the vertebrate cell is a primary cell.

96. The method of claim 74, wherein the vertebrate cell is a transformed, immortal, or malignant cell.

97. The method of claim 74, wherein the vertebrate cell is a cell from which an organism can be reconstituted.

98. The method of claim 74, wherein the cell is selected from the group consisting of an embryonic stem cell, a sperm cell, an ovum, a fertilized ovum, and a somatic repopulating cell.

100. The method of claim 74, wherein the targeting construct provides for a modification rate of at least about 0.1%.

111. The method of claim 74, wherein the recombinant parvovirus particle genome comprises a targeting enhancer.

112. The method of claim 74, wherein the recombinant parvovirus particle genome administered to the cell consists essentially of either all plus strands or all minus strands of the recombinant parvoviral particle genome.

113. The method of claim 74, wherein the cell is treated with an agent that increases targeting efficiency.

114. The method of claim 113, wherein the agent is selected from the group consisting of:

a cell cycle modulator, a DNA repair modulator, a DNA recombination modulator, a modulator of chromatin packaging, an inhibitor of apoptosis, and a DNA methylation inhibitor.

115. The method of claim 74, wherein the modification being introduced is a recombination site.

116. The method of claim 115, wherein the recombination site is a lox site.

121. The method of claim 74, wherein the targeting construct provides for a modification rate of at least about 0.01%.

123. The method of claim 74, wherein the targeting construct provides for a modification rate of 0.01% to 0.1%.

125. The method of claim 74, wherein the targeting construct provides for a modification rate of up to 1%.

77. (canceled)

99. (canceled)

101-110. -110. (canceled)

117-120. -120. (canceled)

122. (canceled)

124. (canceled)

126. (canceled)